Who are Prothena's investors?

Prothena's investors include Sofinnova Ventures, Invesco, RA Capital, Wellington Management.

How much funding has Prothena raised?

Prothena has disclosed $50M raised across 1 of its 2 known rounds.

Where is Prothena headquartered?

Prothena is headquartered in Dun Laoghaire, Co. Dublin, US.

Prothena

NASDAQ: PRTA

Dun Laoghaire, Co. Dublin, US · Founded 2012 · Ireland corporation · 85 employees on LinkedIn · 4 known investors

Find your way into Prothena

Paths you didn't know you had: your email and LinkedIn already hold routes to the Prothena team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins. The company leverages its scientific legacy from Athena Neurosciences and collaborates with academic and industry partners to advance its pipeline of novel therapeutic candidates.

Biotech

Founders & leadership

Tran B. NguyenExecutive

Arthur W. HomanExecutive

Karin L. Walker SVP, Chief Accounting OfficerKarin L. Walker is Chief Accounting Officer at Prothena Corporation plc, bringing three decades of financial management experience across public and private companies in roles including Chief Financial Officer and Controller. She has also served on the boards of Cyclacel Pharmaceutical Inc. and LifeSci Acquisition Corp.

Tara Nickerson, Ph.D.Executive

Wagner M. Zago, Ph.D.Executive

Carol D. Karp Chief Regulatory Officer2016–2025Carol D. Karp is an executive officer at Prothena with extensive regulatory experience across global pharmaceutical and biotechnology companies, including prior roles at CV Therapeutics and Janssen Alzheimer Immunotherapy where she led regulatory strategies and product development from preclinical through commercialization stages.

Gene G. KinneyPresident & Chief Executive Officer

Michael J. MalecekChief Legal Officer and Company Secretary

Brandon S. SmithChief Operating Officer

Chad J. SwansonChief Development Officer

Wagner M. ZagoChief Scientific Officer

Richard T. CollierNamed on SEC filing

Investors · 4

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

InvescoreportedAtlanta

How we know: the S-1 prospectus · Not right? Tell us

RA CapitalreportedBoston

How we know: the S-1 prospectus · Not right? Tell us

Wellington ManagementreportedBoston · $5M – $50M

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$50M disclosed across 1 of 2 rounds · 2017–2018

▶$50MraisedMar 2018 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Richard T. CollierDirector
Tran B. NguyenExecutive Officer
Arthur W. HomanExecutive Officer
Lars G. Eckman, M.D., Ph.D.Director
Dennis J. SelkoeDirector
Karin L. WalkerExecutive Officer
Tara Nickerson, Ph.D.Executive Officer
Wagner M. Zago, Ph.D.Executive Officer
Christopher S. Henney, Ph.D., D.Sc.Director
Carol D. KarpExecutive Officer
Shane M. CookeDirector
Anders O. Harfstrand, M.D., Ph.D.Director
Gene G. Kinney, Ph.D.Executive Officer, Director

Offering amount: $50M
Amount sold: $50M
First sale: Mar 2018
Incorporated: Corporation, Ireland
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$465.9Mvaluation at IPOOct 2013 · $22.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 3

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

Companies working in the same space as Prothena.

Frequently asked questions

What does Prothena do?: Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins. The company leverages its scientific legacy from Athena Neurosciences and collaborates with academic and industry partners to advance its pipeline of novel therapeutic candidates.
Who are Prothena's investors?: Prothena's investors include Sofinnova Ventures, Invesco, RA Capital, Wellington Management.
How much funding has Prothena raised?: Prothena has disclosed $50M raised across 1 of its 2 known rounds.
Where is Prothena headquartered?: Prothena is headquartered in Dun Laoghaire, Co. Dublin, US.